Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival

• Published in: BMC genomics 2022-12, Vol.23 (1), p.1-792, Article 792
• Main Authors: Villanueva, Jonathan W, Kwong, Lawrence, Han, Teng, Martinez, Salvador Alonso, Shanahan, Michael T, Kanke, Matt, Dow, Lukas E, Danko, Charles G, Sethupathy, Praveen
• Format: Article
• Language: English
• Subjects: Animal models; Biological models; Cancer; Cell survival; Cellular control mechanisms; Clinical outcomes; Clinical trials; Colorectal cancer; Colorectal carcinoma; CRISPR/Cas9; Development and progression; Gene expression; Genetic aspects; Genetic modification; Genomes; Genomics; Genotype & phenotype; Genotypes; Health aspects; Heterogeneity; MicroRNA; MicroRNAs; miRNA; Mutation; Oncology, Experimental; Organoid; Organoids; Organs, Culture of; Patients; Precision medicine; Regulatory mechanisms (biology); Ribonucleic acid; RNA; Survival; Therapeutic targets; Tumor heterogeneity; Tumors
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/s12864-022-09018-1

Somatic mutations drive colorectal cancer (CRC) by disrupting gene regulatory mechanisms. Distinct combinations of mutations can result in unique changes to regulatory mechanisms leading to variability in the efficacy of therapeutics. MicroRNAs are important regulators of gene expression, and their activity can be altered by oncogenic mutations. However, it is unknown how distinct combinations of CRC-risk mutations differentially affect microRNAs. Here, using genetically-modified mouse intestinal organoid (enteroid) models, we identify 12 different modules of microRNA expression patterns across different combinations of mutations common in CRC. We also show that miR-24-3p is aberrantly upregulated in genetically-modified mouse enteroids irrespective of mutational context. Furthermore, we identify an enrichment of miR-24-3p predicted targets in downregulated gene lists from various mutational contexts compared to WT. In follow-up experiments, we demonstrate that miR-24-3p promotes CRC cell survival in multiple cell contexts. Our novel characterization of genotype-specific patterns of miRNA expression offer insight into the mechanisms that drive inter-tumor heterogeneity and highlight candidate microRNA therapeutic targets for the advancement of precision medicine for CRC.